Heparin-Binding Protein and Heparins

Cardiovascular Diseases Clinical Trial

— HepHep  

Official title:

Heparin-binding Protein and Heparins

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04146493
• Other study ID #: 4-2957/2017
• Status: Completed
• Start date: April 1, 2019
• Est. completion date: November 30, 2021

Study information

• Verified date: November 2023
• Source: Karolinska University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Heparin-Binding protein is a protein from primary and secretory granluae of white blood cells. It is released when white blood cells become activated and has been advocated as a biomarker for sepsis. The aim of this study is to find out if Heparins in clinical doses can change the level of Heparin-binding protein in plasma.

Description:

Blood samples are taken from patients before and after Heparins in clinical doses. The effects of heparins on Heparin-binding protein concentration in plasma is measured. This is a small observational study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: November 30, 2021
• Est. primary completion date: November 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Planned endovascular treatment of aortic aneurysm or peripheral vascular surgery where unfractionated heparin in >3000 units are given perioperatively

• Planned subcutaneous low molecular weight heparin as a thromboprophylactic treatment after major surgery or on Intensive Care treated patients.

• Planned open heart surgery with cardiopulmonary bypass.

Exclusion Criteria:

• Under 18 years

• Unable to get informed consent from patient or relative

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Thromboprophylaxis
• Vascular Disease, Peripheral
• Vascular Diseases

Intervention

Diagnostic Test:
• Blood samples for Heparin-binding protein measurement
Blood samples before and after given heparin

Locations

Country	Name	City	State
Sweden	Halla Halldorsdottir	Stockholm	Solna

Sponsors (2)

Lead Sponsor	Collaborator
Halla Halldorsdottir	Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the level of Heparin-binding protein	Blood samples are taken before and after given heparin	Repeated blood sampling during minimum of 1 hour and maximum of 5 hours after given heparin